Rebalancing metal dyshomeostasis for Alzheimer’s disease therapy

Guan Jun Yang; Hao Liu; Edmond Dik Lung Ma; Chung Hang Leung

doi:10.1007/s00775-019-01712-y

Rebalancing metal dyshomeostasis for Alzheimer’s disease therapy

Guan Jun Yang, Hao Liu, Edmond Dik Lung Ma, Chung Hang Leung^*

^*Corresponding author for this work

Department of Chemistry

Research output: Contribution to journal › Review article › peer-review

28 Citations (Scopus)

Abstract

Alzheimer’s disease (AD) is a type of neurodegenerative malady that is associated with the accumulation of amyloid plaques. Metal ions are critical for the development and upkeep of brain activity, but metal dyshomeostasis can contribute to the development of neurodegenerative diseases, including AD. This review highlights the association between metal dyshomeostasis and AD pathology, the feasibility of rebalancing metal homeostasis as a therapeutic strategy for AD, and a survey of current drugs that action via rebalancing metal homeostasis. Finally, we discuss the challenges that should be overcome by researchers in the future to enable the practical use of metal homeostasis rebalancing agents for clinical application.

Original language	English
Pages (from-to)	1159-1170
Number of pages	12
Journal	Journal of Biological Inorganic Chemistry
Volume	24
Issue number	8
DOIs	https://doi.org/10.1007/s00775-019-01712-y
Publication status	Published - 1 Dec 2019

Scopus Subject Areas

Biochemistry
Inorganic Chemistry

User-Defined Keywords

Alzheimer’s disease
Aβ aggregation inhibitors
Metal chelators
Metal dyshomeostasis
Metal ions
Multifunctional agents

Access to Document

10.1007/s00775-019-01712-y

Cite this

@article{6034c592ad4f45d5b314684b5c1b6293,

title = "Rebalancing metal dyshomeostasis for Alzheimer{\textquoteright}s disease therapy",

abstract = "Alzheimer{\textquoteright}s disease (AD) is a type of neurodegenerative malady that is associated with the accumulation of amyloid plaques. Metal ions are critical for the development and upkeep of brain activity, but metal dyshomeostasis can contribute to the development of neurodegenerative diseases, including AD. This review highlights the association between metal dyshomeostasis and AD pathology, the feasibility of rebalancing metal homeostasis as a therapeutic strategy for AD, and a survey of current drugs that action via rebalancing metal homeostasis. Finally, we discuss the challenges that should be overcome by researchers in the future to enable the practical use of metal homeostasis rebalancing agents for clinical application.",

keywords = "Alzheimer{\textquoteright}s disease, Aβ aggregation inhibitors, Metal chelators, Metal dyshomeostasis, Metal ions, Multifunctional agents",

author = "Yang, {Guan Jun} and Hao Liu and Ma, {Edmond Dik Lung} and Leung, {Chung Hang}",

note = "Funding Information: This work is supported by Hong Kong Baptist University (FRG2/17-18/003, China), the Health and Medical Research Fund (HMRF/14150561, China), the National Natural Science Foundation of China (21575121 and?21775131, China), the Hong Kong Baptist University Century Club Sponsorship Scheme 2018 (China), the Interdisciplinary Research Matching Scheme (RC-IRMS/16-17/03, China), Interdisciplinary Research Clusters Matching Scheme (RC-IRCs/17-18/03, China), Collaborative Research Fund (C5026-16G, China), SKLEBA and HKBU Strategic Development Fund (SKLP_1718_P04, China), the Funded by The Science and Technology Development Fund, Macau SAR (File no. 077/2016/A2 and SKL-QRCM-2017-2019) and the University of Macau (MYRG2016-00151-ICMS-QRCM and MYRG2018-00187-ICMS, China).",

year = "2019",

month = dec,

day = "1",

doi = "10.1007/s00775-019-01712-y",

language = "English",

volume = "24",

pages = "1159--1170",

journal = "Journal of Biological Inorganic Chemistry",

issn = "0949-8257",

publisher = "Springer Verlag",

number = "8",

}

TY - JOUR

T1 - Rebalancing metal dyshomeostasis for Alzheimer’s disease therapy

AU - Yang, Guan Jun

AU - Liu, Hao

AU - Ma, Edmond Dik Lung

AU - Leung, Chung Hang

N1 - Funding Information: This work is supported by Hong Kong Baptist University (FRG2/17-18/003, China), the Health and Medical Research Fund (HMRF/14150561, China), the National Natural Science Foundation of China (21575121 and?21775131, China), the Hong Kong Baptist University Century Club Sponsorship Scheme 2018 (China), the Interdisciplinary Research Matching Scheme (RC-IRMS/16-17/03, China), Interdisciplinary Research Clusters Matching Scheme (RC-IRCs/17-18/03, China), Collaborative Research Fund (C5026-16G, China), SKLEBA and HKBU Strategic Development Fund (SKLP_1718_P04, China), the Funded by The Science and Technology Development Fund, Macau SAR (File no. 077/2016/A2 and SKL-QRCM-2017-2019) and the University of Macau (MYRG2016-00151-ICMS-QRCM and MYRG2018-00187-ICMS, China).

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Alzheimer’s disease (AD) is a type of neurodegenerative malady that is associated with the accumulation of amyloid plaques. Metal ions are critical for the development and upkeep of brain activity, but metal dyshomeostasis can contribute to the development of neurodegenerative diseases, including AD. This review highlights the association between metal dyshomeostasis and AD pathology, the feasibility of rebalancing metal homeostasis as a therapeutic strategy for AD, and a survey of current drugs that action via rebalancing metal homeostasis. Finally, we discuss the challenges that should be overcome by researchers in the future to enable the practical use of metal homeostasis rebalancing agents for clinical application.

AB - Alzheimer’s disease (AD) is a type of neurodegenerative malady that is associated with the accumulation of amyloid plaques. Metal ions are critical for the development and upkeep of brain activity, but metal dyshomeostasis can contribute to the development of neurodegenerative diseases, including AD. This review highlights the association between metal dyshomeostasis and AD pathology, the feasibility of rebalancing metal homeostasis as a therapeutic strategy for AD, and a survey of current drugs that action via rebalancing metal homeostasis. Finally, we discuss the challenges that should be overcome by researchers in the future to enable the practical use of metal homeostasis rebalancing agents for clinical application.

KW - Alzheimer’s disease

KW - Aβ aggregation inhibitors

KW - Metal chelators

KW - Metal dyshomeostasis

KW - Metal ions

KW - Multifunctional agents

UR - http://www.scopus.com/inward/record.url?scp=85073792170&partnerID=8YFLogxK

U2 - 10.1007/s00775-019-01712-y

DO - 10.1007/s00775-019-01712-y

M3 - Review article

C2 - 31486954

AN - SCOPUS:85073792170

SN - 0949-8257

VL - 24

SP - 1159

EP - 1170

JO - Journal of Biological Inorganic Chemistry

JF - Journal of Biological Inorganic Chemistry

IS - 8

ER -

Rebalancing metal dyshomeostasis for Alzheimer’s disease therapy

Abstract

Scopus Subject Areas

User-Defined Keywords

Access to Document

Other files and links

Fingerprint

Cite this